| Entry |
|
|---|
| Name |
Dasatinib (USAN);
Dasatinib hydrate (JAN);
Sprycel (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C22H26ClN7O2S. H2O
|
|---|
| Exact mass |
505.1663
|
|---|
| Mol weight |
506.02
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00714): | D03658<JP> D06414<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Tyrosine kinase inhibitor |
|---|
| Disease |
Chronic myeloid leukemia (Philadelphia chromosome positive) [DS: H00004] Acute lymphoblastic leukemia (Philadelphia chromosome positive) [DS: H00001] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Network |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EA BCR-ABL tyrosine kinase inhibitors
L01EA02 Dasatinib
D06414 Dasatinib (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, BCR-ABL
Dasatinib
D06414 Dasatinib (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D06414 Dasatinib (USAN); Dasatinib hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00714 Dasatinib
D06414 Dasatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00714 Dasatinib
D06414 Dasatinib
DG02924 UGT substrate
DG00714 Dasatinib
D06414 Dasatinib
Unclassified
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00714 Dasatinib
D06414 Dasatinib
Drug classes [BR:br08332]
Antineoplastic
DG03161 BCR-ABL inhibitor
D06414 Dasatinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFRB
D06414 Dasatinib (USAN) <JP/US>
KIT (CD117)
D06414 Dasatinib (USAN) <JP/US>
EPH family
EPHA2
D06414 Dasatinib (USAN) <JP/US>
Non-receptor tyrosine kinases
SRC family
SRC
D06414 Dasatinib (USAN) <JP/US>
FYN
D06414 Dasatinib (USAN) <JP/US>
LCK
D06414 Dasatinib (USAN) <JP/US>
YES1
D06414 Dasatinib (USAN) <JP/US>
ABL family
BCR-ABL [HSA_VAR:25v1]
D06414 Dasatinib (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06414
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06414
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06414
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06414
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06414
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D06414
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03161 BCR-ABL inhibitor
DG00714 Dasatinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00714 Dasatinib
DG02924 UGT substrate
DG00714 Dasatinib
Unclassified
DG03306 FMO substrate
DG02950 FMO3 substrate
DG00714 Dasatinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 34
1 C8y C 13.3022 -5.7416
2 N5x N 13.3022 -7.1418
3 C8y C 14.5147 -7.8419
4 N5x N 15.7274 -7.1418
5 C8y C 15.7274 -5.7416
6 C8x C 14.5147 -5.0414
7 N1b N 12.0896 -5.0414
8 C8y C 10.8769 -5.7441
9 S2x S 9.7404 -4.9261
10 C8y C 8.6113 -5.7541
11 C8x C 9.0499 -7.0839
12 N5x N 10.4500 -7.0777
13 C1a C 14.5147 -9.2418
14 N1y N 16.9587 -5.0304
15 C1x C 18.1641 -5.7263
16 C1x C 19.3766 -5.0260
17 N1y N 19.3766 -3.6258
18 C1x C 18.1712 -2.9300
19 C1x C 16.9586 -3.6302
20 C1b C 20.5947 -2.9223
21 C1b C 21.8068 -3.6219
22 O1a O 22.9858 -2.9409
23 C5a C 7.4654 -4.9082
24 N1b N 6.1887 -5.4834
25 C8y C 5.0522 -4.6655
26 O5a O 7.4740 -3.5160
27 C8y C 5.0522 -3.2653
28 C8x C 3.8396 -2.5652
29 C8x C 2.6270 -3.2653
30 C8x C 2.6270 -4.6655
31 C8y C 3.8396 -5.3656
32 X Cl 6.2453 -2.5768
33 C1a C 3.8394 -6.7900
34 O0 O 20.3032 -8.7519
BOND 36
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 1
9 8 9 1
10 9 10 1
11 10 11 2
12 11 12 1
13 8 12 2
14 3 13 1
15 5 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 17 18 1
20 18 19 1
21 14 19 1
22 17 20 1
23 20 21 1
24 21 22 1
25 10 23 1
26 23 24 1
27 24 25 1
28 23 26 2
29 25 27 1
30 27 28 2
31 28 29 1
32 29 30 2
33 30 31 1
34 25 31 2
35 27 32 1
36 31 33 1
|
|---|
